Q1 Earnings Estimate for ELDN Issued By Noble Financial

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Stock analysts at Noble Financial issued their Q1 2026 earnings per share estimates for shares of Eledon Pharmaceuticals in a research note issued on Monday, March 23rd. Noble Financial analyst R. Leboyer forecasts that the company will earn ($0.08) per share for the quarter. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Noble Financial also issued estimates for Eledon Pharmaceuticals’ Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($0.91) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its earnings results on Thursday, March 19th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.10.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $9.67.

Eledon Pharmaceuticals Price Performance

Eledon Pharmaceuticals stock opened at $2.92 on Wednesday. Eledon Pharmaceuticals has a one year low of $1.35 and a one year high of $4.60. The business’s fifty day moving average is $2.40 and its 200 day moving average is $2.35. The stock has a market capitalization of $221.48 million, a PE ratio of -5.62 and a beta of 0.84.

Hedge Funds Weigh In On Eledon Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. ADAR1 Capital Management LLC purchased a new stake in Eledon Pharmaceuticals in the fourth quarter worth about $2,751,000. Jefferies Financial Group Inc. bought a new position in shares of Eledon Pharmaceuticals during the 4th quarter valued at approximately $2,387,000. Ensign Peak Advisors Inc increased its holdings in Eledon Pharmaceuticals by 94.9% in the 4th quarter. Ensign Peak Advisors Inc now owns 2,464,919 shares of the company’s stock worth $3,722,000 after acquiring an additional 1,200,000 shares in the last quarter. AWM Investment Company Inc. purchased a new stake in Eledon Pharmaceuticals in the 4th quarter worth approximately $1,661,000. Finally, Sphera Funds Management LTD. raised its stake in Eledon Pharmaceuticals by 97.4% during the 4th quarter. Sphera Funds Management LTD. now owns 2,132,131 shares of the company’s stock worth $3,220,000 after acquiring an additional 1,051,898 shares during the period. 56.77% of the stock is owned by institutional investors.

Key Eledon Pharmaceuticals News

Here are the key news stories impacting Eledon Pharmaceuticals this week:

• Neutral Sentiment: Noble Financial published detailed quarterly EPS forecasts for 2026 (Q1: ($0.08), Q2: ($0.23), Q3: ($0.24), Q4: ($0.22)). These estimates give investors updated short-term earnings visibility but do not by themselves signal a change in fundamentals. Noble Financial Estimates
• Negative Sentiment: Noble Financial lowered its FY2026 EPS forecast for Eledon to ($0.91) from a prior ($0.84), increasing expected full‑year losses and suggesting a dimmer near‑term profitability outlook; that downward revision is bearish for the stock. FY2026 Revision
• Negative Sentiment: Short interest rose materially in March — reported short interest of ~8.42M shares as of March 13 (up ~30% vs. Feb 26), representing roughly 12.7% of shares and a ~6.5 days‑to‑cover figure. Higher short exposure can pressure the stock and increase volatility. Short Interest Data

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.